Company: VCYT
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001384101-25-000060
Chunk: 71

Company: VERACYTE, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 71
---
 Healthcare USA, Inc., the healthcare company that offers ThyroSeq v3, is infringing three of the Company’s patents related to molecular testing of thyroid nodules. The complaint seeks treble damages, attorneys’ fees and costs as well as injunctive relief. Sonic Healthcare USA, Inc. has not yet responded to the Company’s complaint.

15

7. Stockholders’ Equity

 Common Stock The Company had reserved shares of common stock for issuance as follows:  March 31, 2025December 31, 2024Stock options and restricted stock units issued and outstanding6,135,010 5,773,382 Stock options and restricted stock units available for grant under stock option plans8,076,382 8,971,566 Common stock available for the Employee Stock Purchase Plan966,979 1,051,407 Total15,178,371 15,796,355 

8. Components of Other Income

Other income, net consists of the following (in thousands of dollars): Three Months Ended March 31, 20252024French research tax credits$214 $570 Interest income2,762 2,695 Gain (loss) on currency revaluation1,546 (560)Other2 43  Total$4,524 $2,748 

9. Segment

The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance.  The Company has a single reporting unit associated with the development and commercialization of diagnostic products and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies in Note 1, Organization, Description of Business and Summary of Significant Accounting Policies. The chief operating decision maker assesses performance of the Company's single segment and decides how to allocate resources based on consolidated net income. Under the current organizational structure, this measure is not discreetly available or required individually for any of the Company’s business activities and is only available at the consolidated level. The monitoring of budgeted versus actual results are used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discreet operating results of the